Navigation Links
Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
Date:1/29/2008

OXFORD, England, January 29 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on controlling immune system responses, announced today that it has successfully raised GBP11 million ($21.8 million) in an oversubscribed second round funding. The investment syndicate includes new investors Goldman Sachs and Invesco Perpetual, as well as existing investors, including Imperial Innovations and Lansdowne Partners.

"Completing this financing is a testament to the potential of Circassia's business, management and technology," said Steve Harris, Circassia's CEO. "We have made good progress advancing our anti-allergy products during the last year, and successfully completing this funding, particularly in the current challenging market conditions, is a strong vote of confidence from a syndicate of world-class investors."

Circassia, whose immune control technologies target allergies and organ rejection, completed an initial investment round of GBP6 million ($11.8 million) in January 2007. During the last year the company has finalised preparations to complete the phase II clinical testing programme for its lead product against cat dander allergy, and finalised the acquisition of its ToleroTrans organ anti-rejection technology. Following this second investment round, Circassia has increased its current cash balance to GBP15 million ($29.8 million), and plans to utilise the funds both to progress its clinical development programmes and to acquire additional technologies that fit its specialty business model.

Circassia's products have the potential to address significant market opportunities. Currently, over 150 million people suffer from allergic rhinitis in the US and Europe, and existing treatments either provide symptomatic relief only or require lengthy specialist physician supervision over a period of many months due to potential serious, even life-threatening, adverse reactions. In contrast, Circassia's technology uses sm
'/>"/>

SOURCE Circassia Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Primera Biosystems Raises $21 Million in Series B Private Round
2. Cellectar, Inc. Raises $13 Million in Private Offering
3. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
4. Anesiva Raises $45 Million in Common Stock Offering
5. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
6. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
9. VisEn Medical Raises $7 Million in Series B Financing
10. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
11. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 ITRA Global, one of the ... commercial real estate, has further expanded its global reach ... and Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman ... ITRA Global / ACORPP (Australian Corporate Property and Projects) ... providing property services to a wide range of clients ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... pharmacies, has an expanded team of Regional Pharmaceutical ... for prescriber offices in their regions, with specific ... have a variety of Regional Pharmaceutical Care Liaisons ... in hepatitis C help prescribers understand all the ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 iLab Solutions, ... the appointment of Siri Bryant as the new Director ... Director of Core Implementations. These two new leadership positions ... customer service by ensuring that iLab continues to meet ... the last four years, iLab has been deployed at ...
Breaking Biology Technology:ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... under study in the world of nanotechnology, just got ... a group of researchers at the University of Colorado ... surprisingly powerful adhesion qualities -- are expected to help ... mechanical devices such as resonators and gas separation membranes, ...
... 23, 2011 Biotechnology leader Divine Skin Inc. (DSKX) ... second quarter. The expanding innovator of personal care solutions ... accelerating sales, which are 79 percent ahead of the ... challenges has been keeping up with demand," said Divine ...
... FMC Corporation (NYSE: FMC ) announced ... exclusive agreements covering global development and supply of Chr. ... will begin commercialization this year of Chr. Hansen,s Nemix ... biological standalone and combination products in the Americas and ...
Cached Biology Technology:Unexpected adhesion properties of graphene may lead to new nanotechnology devices 2Unexpected adhesion properties of graphene may lead to new nanotechnology devices 3Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010 2Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010 3FMC Corporation Announces Exclusive Global Development and Supply Agreements for Chr. Hansen Biological Products 2
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... Yan Liu imagine and assemble intricate structures on a ... DNA molecule, a versatile building material offering near limitless ... issue of Science , Yan and Liu, researchers ... of Chemistry and Biochemistry, reveal for the first time ...
... from grape seeds forces laboratory leukemia cells to commit ... Kentucky. They found that within 24 hours, 76 percent ... the extract. The investigators, who report their findings ... Cancer Research , a journal of the American Association ...
... be one step closer to better drought-tolerant soybean varieties. ... of all proteins and metabolites in soybeans. Once compiled, ... proteins and metabolites in soybeans grown under drought and ... recently released soybean genome, scientists will have a very ...
Cached Biology News:The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes 2The gold standard: Biodesign Institute researchers use nanoparticles to make 3-D DNA nanotubes 3Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds 2Soybean database will help breeders engineer better-performing plants 2
... Saccharomyces cerevisiae, as well as other yeasts, ... molecular biology laboratories. The ability to transform ... and linear DNAs using lithium based buffers ... transformations and library screening easy and reliable, ...
... jetSI-ENDO-FluoF is a ... nm; emission at 520 nm), ... These reagents are used to ... investigate the intracellular delivery and ...
... Designed specifically for high efficiency ... Low toxicity reagent proven to ... range of cell types. Results ... 95% of target gene expression. ...
... siRNA transfection reagent that has been shown ... variety of cell lines. jetSI-ENDO is serum ... protocol. High levels of gene silencing (up ... 20 to 100 nM of siRNA in ...
Biology Products: